TP53 and non-small cell lung carcinoma: Lysogenic Adenovirus has an extensive tissue tropism, exploited in a two-intervention armed clinical trial (NCT01574729) including 58 patients, was conducted to evaluate an oncolytic Adenovirus (rAd-p53) mediated wild-type p53 gene transfer in stage III or IV NSCLC patients [136, 137].